Antimicrobial Drugs and Community-acquired Methicillin-Resistant Staphylococcus aureus, United Kingdom
Verena Schneider-Lindner*†, J. A. Delaney*†, Sandra Dial†‡, Andre Dascal‡, and Samy Suissa*†
Author affiliations: *McGill University Health Center, Montreal, Quebec, Canada; †Royal Victoria Hospital, Montreal, Quebec, Canada; ‡Sir Mortimer B. Davis–Jewish General Hospital, Montreal, Quebec, Canada;
Figure. Annual number of all study participants with methicillin-resistant Staphylococcus aureus (MRSA) recorded for the first time in the General Practice Research Database (GPRD) and no hospitalization in the past 24 months (vertical bars). The annual incidence rate of MRSA per 100,000 adults in the GPRD is indicated by the line above the bars. Data from the GPRD, United Kingdom, 2000–2004.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.